Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race
Celgene shares were hit hard over the last 24 hours as shareholders reacted to a double dose of bad news: A late-stage Revlimid combo study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
